Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration

References

• Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144–67. doi:10.1136/bjophthalmol-2014-305702.
   PubMed Web of Science ®Google Scholar
• D’Amore PA. Vascular endothelial cell growth factor-A: not just for endothelial cells anymore. Am J Pathol. 2007;171:14–18. doi:10.2353/ajpath.2007.070385.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D‘Amore PA. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS One. 2008;3:e3554. doi:10.1371/journal.pone.0003554.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. 2004;26:943–54. doi:10.1002/bies.20092.
   PubMed Web of Science ®Google Scholar
• Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and schwann cell proliferaton in the peripheral nervous system. J Neurosci. 1999;19:5731–40.
   PubMed Web of Science ®Google Scholar
• Demirel S, Batioglu F, Ozmert E, Erenler F. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res. 2015;40:87–92. doi:10.3109/02713683.2014.917190.
   PubMed Web of Science ®Google Scholar
• Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Opthalmol. 2010;150:558–61. doi:10.1016/j.ajo.2010.04.029.
   PubMed Web of Science ®Google Scholar
• Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol. 2015;35:473–80. doi:10.1007/s10792-014-9972-2.
   PubMed Web of Science ®Google Scholar
• Yau GL, Campbell RJ, Li C, Sharma S. Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration. Can J Ophthalmol. 2015;50:345–49. doi:10.1016/j.jcjo.2015.01.008.
   PubMed Web of Science ®Google Scholar
• Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Inves Ophthalmol Vis Sci. 2012;53:6214–18. doi:10.1167/iovs.12-9875.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Kim SN, Chung H, Kim TE, Kim HC. Intravitreal anti-vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: a meta-analysis. Iovs. 2016;57:1798–806.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong I, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67. doi:10.2353/ajpath.2007.061237.
   PubMed Web of Science ®Google Scholar
• Cheng CK, Peng PH, Tien LT, Cai YJ, Chen CF, Lee YJ. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina. 2009;29:306–12. doi:10.1097/IAE.0b013e3181909404.
   PubMed Web of Science ®Google Scholar
• Perdicchi A, Peluso G, Iacovello D, Balestrieri M, Delle Fave M, Abdolrahimzadeh S, Scuderi G, Fenicia V, Recupero SM. Ganglion cell complex evaluation in exudative age-related macular degeneration after repeated intravitreal injections of ranibizumab. Biomed Res Int. 2015;2015:268796. doi:10.1155/2015/268796.
   PubMed Web of Science ®Google Scholar
• Beck M, Munk MR, Ebneter A, Wolf S, Zinkernagel MS. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol. 2016;167:10–17. doi:10.1016/j.ajo.2016.04.003.
   PubMed Web of Science ®Google Scholar
• Staurenghi G, Sadda S, Chakravarthy U, Spaide RF. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography. Ophthalmology. 2014;121:1572–78. doi:10.1016/j.ophtha.2014.02.023.
   PubMed Web of Science ®Google Scholar
• Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals. 2005;14:207–21. doi:10.1159/000088637.
   PubMed Web of Science ®Google Scholar
• Shin HY, Park HY, Jung KI, Park CK. Comparative study of macular ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer measurement: structure-function analysis. Invest Ophthalmol Vis Sci. 2013;54:7344–53. doi:10.1167/iovs.13-12667.
   PubMed Web of Science ®Google Scholar
• Abdolrahimzadeh S, Felli L, Plateroti AM, Perdicchi A, Contestabile MT, Recupero SM. Spectral domain optical coherence tomography evidence of retinal nerve fibre layer and ganglion cell loss in adult patients with neurofibromatosis type 1. Retina. 2016;36:75–81. doi:10.1097/IAE.0000000000000650.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Kim YK, Kim YW, Jeoung JW, Kim SH, Heo JW, Yu HG, Park KH. Rate of macular ganglion cell-inner plexiform layer thinning in glaucomatous eyes with vascular endothelial growth factor inhibition. J Glaucoma. 2017;26:980–86. doi:10.1097/IJG.0000000000000776.
   PubMed Web of Science ®Google Scholar
• Muftuoglu IK, Lin T, Freeman WR. Inner retinal thickening in newly diagnosed choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2018;256:2035–40. doi:10.1007/s00417-018-4093-7.
   PubMed Web of Science ®Google Scholar
• Salah R, Karpe A, Zinkernagel MS, Munk MR. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255:817–24. doi:10.1007/s00417-017-3590-4.
   PubMed Web of Science ®Google Scholar
• Lee EK, Yu HG. Ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer thicknesses in early age-related macular degeneration. Iovs. 2015;56:3976–83.
   PubMed Web of Science ®Google Scholar
• Zucchiatti I, Parodi MB, Pierro L, Cicinelli MV, Gagliardi M, Castellino N, Bandello F. Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration. Am J Ophthalmol. 2015;160:602–07. doi:10.1016/j.ajo.2015.05.030.
   PubMed Web of Science ®Google Scholar
• Hendrickson A, Warner CE, Possin D, Huang J, Kwan WC, Bourne J. Retrograde transneural degeneration in the retina and lateral geniculate nucleus of the VI-lesioned marmoset monkey. Brain Struct Funct. 2015;220:351–60. doi:10.1007/s00429-013-0659-7.
   PubMed Web of Science ®Google Scholar
• Abdolrahimzadeh S, Parisi F, Scavella V, Recupero SM. Optical coherence tomography evidence on the correlation of choroidal thickness and age with vascularized retinal layers in normal eyes. Retina. 2016;36:2329–38. doi:10.1097/IAE.0000000000001097.
   PubMed Web of Science ®Google Scholar
• Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, Ladas I, Vergedos E. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica. 2009;223:383–289. doi:10.1159/000228590.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Lotfi M, Esfahani N, Nassiri N, Khalili MR, Razaghinejad MR, Nouri-Mahdavi K. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina. 2012;32:967–71. doi:10.1097/IAE.0b013e31822c28d6.
   PubMed Web of Science ®Google Scholar
• Sharma NS, Ong JM, Ooi L. Re: fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye. 2015;29:291–92. doi:10.1038/eye.2014.265.
   PubMed Web of Science ®Google Scholar
• Feigl B, Brown B, Lovie-Kitchin J, Swann P. Functional loss in early age-related maculopathy: the ischaemia post receptoral hypothesis. Eye (Lond). 2007;21:689–96. doi:10.1038/sj.eye.6702389.
   PubMed Web of Science ®Google Scholar
• Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27:1044–47. doi:10.1097/IAE.0b013e3180592ba6.
   PubMed Web of Science ®Google Scholar
• Hammel N, Belghith A, Weinreb RN, Medeiros FA, Mendoza N, Zangwill LM. Comparing the rates of retinal nerve fiber layer and ganglion cell-inner plexiform layer loss in healthy eyes and in glaucoma eyes. Am J Ophthalmol. 2017;178:38–50. doi:10.1016/j.ajo.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Zayit-Soudry S, Zemel E, Loewenstein A, Perlman I. Safety evaluation of repeated intravitreal injections of bevacizumab or ranibizumab in rabbit eyes. Retina. 2010;30:671–81. doi:10.1097/IAE.0b013e3181c0858c.
   PubMed Web of Science ®Google Scholar